Former Siga CFO Tom Konatich testified today that Siga originally contacted PharmAthene and offered to license Siga's smallpox drug, ST-246, because Siga needed to improve its cash flow quickly. But in response, according to Mr. Konatich, PharmAthene told him that they were not interested in a license arrangement, and that "it was a merger or nothing."
Former Siga CFO Tom Konatich testifies in PharmAthene v. Siga
Posted by msch on Jan 10, 2011 10:33:00 AM
0 Comments Click here to read/write comments
Topics: Commercial Law, PharmAthene v. Siga